Method for treating cancer patients with severe renal impairment
AssigneeTaiho Pharmaceutical Co., Ltd.
InventorKenichiro Yoshida
Life of this patent
Estimating the term…
Abstract
A method for treating cancer in patients with creatinine clearance of 15 mL/min or more and less than 30 mL/min, including dividing a combination drug containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, in a dose of 30 to 40 mg/m2/day as FTD-equivalent, into two to four times a day, and orally administering it to the patient.
Claims40
A method for treating a solid cancer in a patient with creatinine clearance of 15 mL/min to 29 mL/min, comprising:
- orally administering to the patient a combination drug containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, in a starting dose of 40 mg/m2/day as FTD-equivalent, in two 20 mg/m2 doses a day.
A therapeutic agent for treating a solid cancer in a patient with a creatinine clearance of 15 mL/min to 29 mL/min, wherein the therapeutic agent comprises a combination drug containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, and wherein the therapeutic agent is orally administered to the patient in a starting dose of 40 mg/m2/day as FTD-equivalent in two 20 mg/m2 doses a day.
A combination drug containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5 for treating a solid cancer in a patient with a creatinine clearance of 15 mL/min to 29 mL/min, wherein the combination drug is orally administered to the patient in a starting daily dose of 40 mg/m2/day as FTD-equivalent in two 20 mg/m2 doses a day.
A method for treating a solid cancer in a patient with a creatinine clearance of 15 mL/min to 29 mL/min, comprising:
- orally administering to the patient a combination drug containing α,α,α-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, in a reduced dose of 30 mg/m2/day as FTD-equivalent, in two 15 mg/m2 doses a day;
- wherein the patient is unable to tolerate a starting dose of 40 mg/m2/day as FTD-equivalent, in two 20 mg/m2 doses a day.
Dependencies are inferred from the claim text.